Skip to main content
Top
Published in: AIDS and Behavior 3/2014

01-03-2014 | Original Paper

Whoonga: Potential Recreational Use of HIV Antiretroviral Medication in South Africa

Authors: David J. Grelotti, Elizabeth F. Closson, Jennifer A. Smit, Zonke Mabude, Lynn T. Matthews, Steven A. Safren, David R. Bangsberg, Matthew J. Mimiaga

Published in: AIDS and Behavior | Issue 3/2014

Login to get access

Abstract

Whoonga is a drug cocktail in South Africa rumored to contain illicit drugs and HIV antiretroviral (ARV) medication. Although its use may adversely impact adherence to HIV treatment and may have the potential to generate ARV resistance, there is a paucity of research characterizing whoonga. We learned of whoonga during semi-structured interviews about substance abuse and HIV risk at “club-events” known as inkwaris in an urban township of Durban, South Africa. Whoonga was an emerging theme spontaneously identified as a problem for the community by 17 out of 22 informants. Perceptions of whoonga suggest that it is highly addictive, contains ARVs (notably efavirenz), is used by individuals as young as 14, and poses a threat to the health and safety of those who use it, including increasing the risk of HIV infection. Our informants provide preliminary evidence of the dangers of whoonga and reinforce the need for further study.
Literature
1.
go back to reference Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.PubMedCrossRef Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–15.PubMedCrossRef
2.
go back to reference Fisher JC, Bang H, Kapiga SH. The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies. Sex Transm Dis. 2007;34(11):856–63.PubMedCrossRef Fisher JC, Bang H, Kapiga SH. The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies. Sex Transm Dis. 2007;34(11):856–63.PubMedCrossRef
3.
go back to reference Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci. 2007;8(2):141–51.PubMedCrossRef Kalichman SC, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci. 2007;8(2):141–51.PubMedCrossRef
4.
go back to reference Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRef Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRef
5.
go back to reference Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6(7):e22698.PubMedCentralPubMedCrossRef Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6(7):e22698.PubMedCentralPubMedCrossRef
6.
go back to reference Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.PubMedCrossRef Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.PubMedCrossRef
7.
go back to reference Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171–83.PubMedCentralPubMedCrossRef Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171–83.PubMedCentralPubMedCrossRef
8.
go back to reference Larkan F, Van Wyk B, Saris J. Of remedies and poisons: recreational use of antiretroviral drugs in the social imagination of South African carers. Afr Sociol Rev/Revue Africaine de Sociologie. 2010;14(2):62–73. Larkan F, Van Wyk B, Saris J. Of remedies and poisons: recreational use of antiretroviral drugs in the social imagination of South African carers. Afr Sociol Rev/Revue Africaine de Sociologie. 2010;14(2):62–73.
9.
go back to reference Kasang C, Kalluvya S, Majinge C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One. 2011;6(8):e23091.PubMedCentralPubMedCrossRef Kasang C, Kalluvya S, Majinge C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One. 2011;6(8):e23091.PubMedCentralPubMedCrossRef
13.
go back to reference Michel J. The challenges experienced by non-governmental organizations with regard to the rollout of antiretroviral drugs in KwaZulu Natal. University of South Africa; 2012. Michel J. The challenges experienced by non-governmental organizations with regard to the rollout of antiretroviral drugs in KwaZulu Natal. University of South Africa; 2012.
14.
go back to reference The South African National Treatment Guidelines 2010. Johannesburg: National Department of Health South Africa; 2010. The South African National Treatment Guidelines 2010. Johannesburg: National Department of Health South Africa; 2010.
18.
go back to reference The 2011 National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa. Johannesburg: National Department of Health South Africa; 2012. The 2011 National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa. Johannesburg: National Department of Health South Africa; 2012.
19.
go back to reference Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral exposure from recreational use. Lancet Infect Dis. 2013;13(1):10–2.PubMedCrossRef Grelotti DJ, Closson EF, Mimiaga MJ. Pretreatment antiretroviral exposure from recreational use. Lancet Infect Dis. 2013;13(1):10–2.PubMedCrossRef
20.
go back to reference Mimiaga MJ, Smit J, Closson EF, et al. Inkwari: an emerging high-risk venue potentiating HIV spread among adolescents and young adults in a hyperendemic South African setting. 19th International AIDS Conference, Washington, DC, 22–27 July 2012. Mimiaga MJ, Smit J, Closson EF, et al. Inkwari: an emerging high-risk venue potentiating HIV spread among adolescents and young adults in a hyperendemic South African setting. 19th International AIDS Conference, Washington, DC, 22–27 July 2012.
21.
go back to reference Altheide DL. Qualitative media analysis. Thousand Oaks: Sage Publications, Inc; 1996. Altheide DL. Qualitative media analysis. Thousand Oaks: Sage Publications, Inc; 1996.
22.
go back to reference Silverman D. Doing qualitative research: a practical handbook. 3rd ed. Thousand Oaks: Sage; 2010. Silverman D. Doing qualitative research: a practical handbook. 3rd ed. Thousand Oaks: Sage; 2010.
24.
go back to reference Sustiva (efavirenz) package insert. Princeton: Bristol-Myers Squibb; 2012. Sustiva (efavirenz) package insert. Princeton: Bristol-Myers Squibb; 2012.
25.
go back to reference Gatch MB, González Maeso J, Huang RQ, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology. 2013. Gatch MB, González Maeso J, Huang RQ, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology. 2013.
26.
go back to reference Blanch J, Corbella B, Garcia F, Parellada E, Gatell JM. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001;33(2):270–1.PubMedCrossRef Blanch J, Corbella B, Garcia F, Parellada E, Gatell JM. Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001;33(2):270–1.PubMedCrossRef
27.
go back to reference Boscacci RT, Buclin T, Furrer H, Fux CA. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006;20(9):1352–4.PubMedCrossRef Boscacci RT, Buclin T, Furrer H, Fux CA. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006;20(9):1352–4.PubMedCrossRef
28.
go back to reference van Heerden MS, Grimsrud AT, Seedat S, Myer L, Williams DR, Stein DJ. Patterns of substance use in South Africa: results from the South African stress and health study. S Afr Med J. 2009;99(5 Pt 2):358–66.PubMedCentralPubMed van Heerden MS, Grimsrud AT, Seedat S, Myer L, Williams DR, Stein DJ. Patterns of substance use in South Africa: results from the South African stress and health study. S Afr Med J. 2009;99(5 Pt 2):358–66.PubMedCentralPubMed
29.
go back to reference Myers B, Siegfried N, Parry CD. Over-the-counter and prescription medicine misuse in Cape Town–findings from specialist treatment centres. S Afr Med J. 2003;93(5):367–70.PubMed Myers B, Siegfried N, Parry CD. Over-the-counter and prescription medicine misuse in Cape Town–findings from specialist treatment centres. S Afr Med J. 2003;93(5):367–70.PubMed
30.
go back to reference Parry CD, Bhana A, Pluddemann A, et al. The South African Community Epidemiology Network on Drug Use (SACENDU): description, findings (1997–1999) and policy implications. Addiction. 2002;97(8):969–76.PubMedCrossRef Parry CD, Bhana A, Pluddemann A, et al. The South African Community Epidemiology Network on Drug Use (SACENDU): description, findings (1997–1999) and policy implications. Addiction. 2002;97(8):969–76.PubMedCrossRef
31.
go back to reference Dada S, Plüddermann A, Williams Y, et al. South African Community Epidemiology Network on Drug Use (SACENDU): Monitoring Alcohol and Drug Abuse Treatment Admissions in South Africa. Johannesburg: South African Community Epidemiology Network on Drug Use (SACENDU); 2012. Dada S, Plüddermann A, Williams Y, et al. South African Community Epidemiology Network on Drug Use (SACENDU): Monitoring Alcohol and Drug Abuse Treatment Admissions in South Africa. Johannesburg: South African Community Epidemiology Network on Drug Use (SACENDU); 2012.
32.
go back to reference Mackie N. Resistance to non-nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral resistance in clinical practice. London: Mediscript; 2006. Mackie N. Resistance to non-nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral resistance in clinical practice. London: Mediscript; 2006.
Metadata
Title
Whoonga: Potential Recreational Use of HIV Antiretroviral Medication in South Africa
Authors
David J. Grelotti
Elizabeth F. Closson
Jennifer A. Smit
Zonke Mabude
Lynn T. Matthews
Steven A. Safren
David R. Bangsberg
Matthew J. Mimiaga
Publication date
01-03-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0575-0

Other articles of this Issue 3/2014

AIDS and Behavior 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.